This inventor holds 1 USPTO granted patent. Top assignees: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Seattle Children's Hospital, Stellenbosch University. Active years: 2023.
Company Filing History:
1 out of 1,330 
1 out of 88 
1 out of 76 
Years Active: 2023
Title: Sara Suliman: Innovator in Tuberculosis Research
Introduction
Sara Suliman is a prominent inventor based in Brookline, MA (US). She has made significant contributions to the field of medical research, particularly in the area of tuberculosis (TB). Her innovative work focuses on predicting the progression of latent TB infections to active disease, which is crucial for timely intervention and treatment.
Latest Patents
Sara Suliman holds a patent for a groundbreaking invention titled "Method for predicting progression to active tuberculosis disease." This invention provides a gene signature that helps determine the likelihood of a latent TB infection transitioning to active TB disease. The gene signature includes at least SEPT4 and BLK, and may also involve GAS6 and/or CD1C. By detecting the expression levels of these genes in a subject's sample, ratios of expression are calculated, which are then used to assign scores indicative of the likelihood of progression to active TB disease.
Career Highlights
Throughout her career, Sara has worked with esteemed institutions such as the University of Cape Town and Stellenbosch University. Her research has been pivotal in advancing our understanding of tuberculosis and improving diagnostic methods.
Collaborations
Sara has collaborated with notable colleagues, including Ethan Greene Thompson and Jayne Suzanne Sutherland. These partnerships have enriched her research and contributed to the development of her innovative patent.
Conclusion
Sara Suliman's work exemplifies the impact of innovation in medical research, particularly in combating tuberculosis. Her patented method offers a promising approach to predicting disease progression, ultimately aiding in better patient outcomes.